Smith Thornton Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-4,615
Closed -$227K – 145
2026
Q2
$227K Buy
+4,615
New +$198K 0.1% 126
2024
Q3
– Sell
-1,583
Closed -$226K – 138
2024
Q2
$226K Buy
+1,583
New +$210K 0.17% 118

Other funds holding NVO

Smith Thornton Advisors's NVO Position: Q3 2026 in Review

Smith Thornton Advisors sold out of Novo Nordisk (NVO) in Q3 2026, closing a stake of 4,615 shares — an estimated $227K sold.

Smith Thornton Advisors first reported a position in NVO in Q2 2024 and held it in 2 quarters. The position peaked at $227K in Q2 2026. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Smith Thornton Advisors reported no remaining Novo Nordisk position as of Q3 2026 after selling out during the quarter.
  • Smith Thornton Advisors sold 4,615 Novo Nordisk shares in Q3 2026, an estimated $227K.
  • Smith Thornton Advisors first reported a position in Novo Nordisk in Q2 2024 and held it in 2 quarters.
  • Smith Thornton Advisors's Novo Nordisk position peaked at $227K in Q2 2026.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Smith Thornton Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.